Skip directly to content

2018 Publications

PIpeline Report 2018
July 23, 2018 – Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

TAGline, Spring 2018
April 4, 2018 – In this issue of TAGline, we highlight some important recent successes and challenges in meeting TAG’s overarching goals: moving beyond achingly slow trends and sharply bending the curves on new HIV, hepatitis C, and tuberculosis infections, suffering, and deaths.

Is Shorter Better? Understanding the Shorter Regimen for Treating Drug-Resistant Tuberculosis
March 12, 2018 – Confused about the shorter regimen for treating Multidrug-resistant TB (MDR-TB)? We were too, so we worked with DR-TB STAT on a brief to understand its pros and cons.

TAG Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy
March 5, 2018 - Antitretroviral therapy is highly effective at suppressing HIV viral load, but for some individuals this does not lead to adequate reconstitution of the immune system. TAG's issue brief offers an overview of suboptimal immune recovery on antiretroviral therapy, and explains why it remains an important concern.

Know Your Rights: Tuberculosis Prevention, Diagnosis, and Treatment Guide
February 5, 2018 – We recently released this innovative new guide for people who have tuberculosis (TB), people who are at risk for it, and the people who take care of them.

Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
February 1, 2018 – We've just released an updated Training Manual for Treatment Activists: Hepatitis C and HIV Coinfection. The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV).

Securing a Tuberculosis-Free Future through the Visionary Research of the CDC’s Tuberculosis Trials Consortium
January 10, 2018 – The Tuberculosis Trials Consortium (TBTC) is a global leader in research and development for better tools to prevent, diagnose, and treat tuberculosis (TB). Housed within the U.S. Centers for Disease Control and Prevention (CDC), the TBTC conducts clinical research of high public health relevance and is key to strengthening domestic and global campaigns to eliminate TB. TBTC studies have produced several notable breakthroughs, including a shorter regimen for preventing TB (3HP) using isoniazid and rifapentine.